Excalipoint Therapeutics
Develops next-generation T-cell engager therapies for cancer and autoimmune diseases
$27.7MSeed+
Role not disclosedM
MPCi
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026
MPCi is the China-focused investment manager identified by its own site and by Tripo, Aureka and Excalipoint announcements.
Recorded funding activity
Tripo develops generative 3D tools. Aureka builds biological models and discovery infrastructure, while Excalipoint develops T-cell therapies. The manager remains distinct from US Matrix and independently operated regional firms.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $27.7M 1 disclosed · full round size, not this investor’s share